74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
India Globalization Capital Inc
Closed
0.28
Overview
Share price change
24h
Min
0.28
Max
0.29
Income | -112K -1.8M |
|---|---|
Sales | -155K 257K |
Profit margin | -711.673 |
Employees | 67 |
EBITDA | -263K -1.9M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +1417.86% upside |
Next Earnings | 20 Jun 2025 |
|---|
Market Cap | 23M |
|---|---|
Previous open | 0.28 |
Previous close | 0.28 |
India Globalization Capital Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
India Globalization Capital Inc Forecast
Price Target
By TipRanks
1417.86% upside
12 Months Forecast
Average 4.25 USD 1417.86%
High 4.25 USD
Low 4.25 USD
Based on 1 Wall Street analysts offering 12 month price targets forIndia Globalization Capital Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
